FDA Oversight Of Clinical Trials Needs More Muscle, OIG Report Says
This article was originally published in The Gray Sheet
Executive Summary
FDA lacks the data it needs to protect patients enrolled in clinical trials, says a Sept. 28 1report from the HHS Office of Inspector General